AU7602800A - Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof - Google Patents

Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Info

Publication number
AU7602800A
AU7602800A AU76028/00A AU7602800A AU7602800A AU 7602800 A AU7602800 A AU 7602800A AU 76028/00 A AU76028/00 A AU 76028/00A AU 7602800 A AU7602800 A AU 7602800A AU 7602800 A AU7602800 A AU 7602800A
Authority
AU
Australia
Prior art keywords
hvr1
hepatitis
lacks
protein
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76028/00A
Inventor
Jens Bukh
Suzanne U Emerson
Xavier Forns
Robert H. Purcell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Government filed Critical US Department of Health and Human Services
Publication of AU7602800A publication Critical patent/AU7602800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect
AU76028/00A 1999-09-23 2000-09-22 Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof Abandoned AU7602800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15582399P 1999-09-23 1999-09-23
US60/155823 1999-09-23
PCT/US2000/025987 WO2001021807A1 (en) 1999-09-23 2000-09-22 Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Publications (1)

Publication Number Publication Date
AU7602800A true AU7602800A (en) 2001-04-24

Family

ID=22556944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76028/00A Abandoned AU7602800A (en) 1999-09-23 2000-09-22 Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Country Status (2)

Country Link
AU (1) AU7602800A (en)
WO (1) WO2001021807A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682909B2 (en) * 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof
US20060222661A1 (en) * 2002-09-13 2006-10-05 Birke Bartosch Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
CA2501946C (en) 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
US7361503B2 (en) 2003-11-12 2008-04-22 Albert Einstein College Of Medicine Of Yeshiva University Sequences encoding hepatitis C virus glycoproteins
CN101563362B (en) * 2006-08-25 2015-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 Recombinant HCV E2 glycoprotein
WO2008125117A1 (en) 2007-04-13 2008-10-23 Hvidovre Hospital Cell culture system of a hepatitis c genotype 3a and 2a chimera
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
US8618275B2 (en) 2007-05-18 2013-12-31 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 5A
WO2009080052A1 (en) 2007-12-20 2009-07-02 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 6a
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
US8663653B2 (en) 2008-08-15 2014-03-04 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 2B
WO2010017819A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a
EP2344647A1 (en) 2008-10-03 2011-07-20 Hvidovre Hospital Hepatitis c virus expressing reporter tagged ns5a protein
WO2012075104A2 (en) * 2010-11-30 2012-06-07 The Trustees Of Columbia University In The City Of New York Novel non-primate hepacivirus
WO2018176075A1 (en) * 2017-03-27 2018-10-04 The University Of Queensland Chimeric insect-specific flaviviruses
US20230181726A1 (en) * 2020-05-11 2023-06-15 Macfarlane Burnet Institute For Medical Research And Public Health Limited A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE249838T1 (en) * 1993-05-12 2003-10-15 Chiron Corp PRESERVED MOTIF OF THE HEPATITIS C VIRUS E2/NS1 REGION
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof

Also Published As

Publication number Publication date
WO2001021807A8 (en) 2001-10-11
WO2001021807A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
ZA981838B (en) Functional DNA clone for hepatitis C virus (HCV) and uses thereof
DE69933433D1 (en) VIRUS-CONTAINING COMPOSITIONS AND METHODS FOR CONCENTRATING VIRUS PREPARATIONS
WO1999004008A3 (en) Cloned genomes of infectious hepatitis c viruses and uses thereof
ID21649A (en) INHIBITOR SERUM PROTEASE, ESPECIALLY VIRUS HEPATITIS C NS3 PROTEASE
UA85536C2 (en) Viral antigens
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
AU6591998A (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein
ZA9811316B (en) Novel hepatitis C virus NS5B protein
AU3714499A (en) Hepatitis c virus mimotopes
AU2001232267A1 (en) Remedies for hepatitis c
AU3990799A (en) Viral characterization by direct detection of capsid proteins
AU2002250078A1 (en) Quantitative epstein barr virus pcr rapid assay
IL143798A0 (en) Hepatitis c virus ns3 protease
EP1100545A4 (en) Regulated expression of recombinant proteins using rna viruses
IL138804A0 (en) Hepatitis c virus ns5b nucleic acids and proteins
WO1999004029A3 (en) A swine hepatitis e virus and uses thereof
EP1113777A4 (en) Novel hepatitis c virus peptides and uses thereof
AU3184701A (en) Mutated hepatitis B virus, its nucleic and protein constituents and uses thereof
AU7917200A (en) Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
WO2004037202A3 (en) Gb virus c and methods of treating viral infections
AU4335099A (en) Surface targeted expression of a modified hepatitis c virus envelope protein
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU5924396A (en) Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase